Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy

Breast

Volumn 19, Issue 2, 2010, Pages 76-83

  Josefsson, Mette L ^a   Leinster, Samuel J ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Adjuvant hormonal therapy; Aromatase inhibitor; Breast cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FRACTURE; GYNECOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; INTERNAL VALIDITY; MENOPAUSAL SYNDROME; META ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

EID: 77951203576     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.12.010     Document Type: Review

References (54)

1. National Institute for Health and Clinical Excellence NICE technology appraisal guidance 112. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer 2006, National Institute for Health and Clinical Excellence.
2. Nadji M., Gomez-Fernandez C., Ganjei-Azar P., Morales A. Immunohistochemistry of estrogen and progesterone receptors considered: experience with 5,993 breast cancers. Am J Clin Pathol 1998, 123:21-27. 10.1309/4WV79N2GHJ3X1841.
3. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998, 33:1609-1618.
4. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467. Early Breast Cancer Trialists' Collaborative Group. 10.1016/S0140-6736(97)11423-4.
5. Love R.R., Barden H.S., MAzess R.B., Epstein S., Chappell R.J. Effect of tamoxifen on lumbar spine mineral density in postmenopausal women after 5 years. Arch Intern Med 1994, 154:2585-2588.
6. McDonald C.C., Alexander F.E., Whyte B.W., Forrest A.P., Stewart H.J. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 1995, 311:977-980.
7. The American College of Obstetricians and Gynaecologists Tamoxifen and endometrial cancer. Obstet Gynecol 2000, 95:1C-3C.
8. Clarke R., Skaar T.C., Bouker K.B., Davis N., Lee Y.R., Welch J.N., et al. Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol. 2001, 76:71-84. 10.1016/S0960-0760(00)00193-X.
9. Brewster A.M., Hortobagyi G.N., Broglio K.R., Kau S.W., Santa-Maria C.A., Arun B., et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008, 100:1179-1183. 10.1093/jnci/djn233.
10. Saphner T., Torney D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.
11. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialist's Collaborative Group. 10.1016/S0140-6736(05)66544-0.
12. Barron T.I., Roisin C., Bennet K., Feely J., Kennedy M.J. Early discontinuation of tamoxifen. Cancer 2007, 109:1-9. 10.1002/cncr.22485.
13. Miller W.R., Bartletta J., Brodeib A.M., Brueggemeier R.W., di Salle E., Lønning P.E., et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist 2008, 13:829-837. 10.1634/theoncologist.2008-0055.
14. Monnier A. Effects of adjuvant aromatase inhibitor therapy on lipid profiles. Expert Rev Anticancer Ther. 2006, 6:1653-1662. 10.1586/14737140.6.11.1653.
15. Berry J. Are all Aromatase Inhibitors the same? a review of controlled clinical trials in breast cancer. Clin Ther 2005, 27:1671-1684.
16. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092. [see comment] [erratum appears in N Engl J Med. 2004 Dec 2;351(23):2461.
17. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
18. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
19. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139. 10.1016/S0140-6736(02)09088-8.
20. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271. 10.1093/jnci/dji250.
21. Jonat W., Gnant M., Boccardo F. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006, 7:991-996. 10.1016/S1470-2045(06)70948-2.
22. Jakesz R., Gnant M., Griel R. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Cancer Res. 2009, 69:67.
23. Winer E.P., Hudis C., Burstein H.J., Wolff A.C., Pritchard K.I., Ingle J.N., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005, 23:619-629. 10.1200/JCO.2005.09.121.
24. Higgins J.P.T., Altman D.G. Assessing risk of bias in included studies. Cochrane Handbook for Systematic reviews of Interventions 2008, The Cochrane Collaboration. J.P.T. Higgins, S. Green (Eds.).
25. Aksoy S., Altundag K., Dizdar O. Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment [letter]. Breast 2008, 17:433-435. 10.1016/j.breast.2008.05.003.
26. Jones S.E., Seynaeve C., Hasenburg A. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res. 2009, 69:67.
27. Mamounas E.P., Lembersky B., Jeong J.-H., Cronin W., Harkins B., Geyer C., et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2006, 7:416-421.
28. Schmid M., Jakesz R., Samonigg H., Kubista E., Gnant M., Menzel C., et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: austrian breast and colorectal cancer study group trial 6. J Clin Oncol. 2003, 21:984-990. 10.1200/JCO.2003.01.138.
29. Boccardo F., Rubagotti A., Amoroso D., Mesiti M., Romeo D., Caroti C., et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol. 2001, 19:4209-4215.
30. The Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group, Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.[see The Arimidex Tamoxifen Alone or in Combination Trialists' Group, comment]. Lancet Oncol 2008, 9:45-53. 10.1016/S1470-2045(07)70385-6.
31. Jakesz R., Kaufmann M., Gnant M. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004, 88:S7.
32. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98:1802-1810. 10.1002/cncr.11745.
33. Buzdar A. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. Clin Breast Cancer 2003, 4(Suppl. 1):S42-S48.
34. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A., Howell A., Cuzick J., Wale C., Distler W., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006, 7:633-643. The Arimidex TAoiCTG. 10.1016/S1470-2045(06)70767-7.
35. Cuzick J. The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer. Expert Rev Anticancer Ther 2007, 7:1089-1094. 10.1586/14737140.7.8.1089.
36. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. [see comment]. J Clin Oncol. 2007, 25:486-492. 10.1200/JCO.2006.08.8617.
37. Koeberle D., Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Research & Treatment 2007, 105(Suppl 1):55-66. 10.1007/s10549-9700-y.
38. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776. Breast International Group 1-98 Collaborative Group.
39. Kaufmann M., Jonat W., Hilfrich J., Eidtmann H., Gademann G., Zuna I., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007, 25:2664-2670. 10.1200/JCO.2006.08.8054.
40. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570. 10.1016/S0140-6736(07)60200-1.
41. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005, 23:5138-5147. 10.1200/JCO.2005.04.120.
42. Boccardo F., Rubagotti A., Guglielmini P., Fini A., Paladini G., Mesiti M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Annals of Oncology 2006, 17(Suppl. 7):vii10-vii14. 10.1093/annonc/mdl941.
43. Ingle J.N., Tu D., Pater J.L., Muss H.B., Martino S., Robert N.J., et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of Oncology 2008, 19:877-882. 10.1093/annonc/mdm566.
44. Mamounas E.P., Jeong J.-H., Wickerham D.L., Smith R.E., Ganz P.A., Land S.R., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008, 26:1965-1971. 10.1200/JCO.2007/14.0228.
45. Jakesz R., Greil R., Gnant M., Schmid M., Kwasny W., Kubista E., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007, 99:1845-1853. 10.1093/jnci/djm246.
46. Whelan T.J., Goss P.E., Ingle J.N., Pater J.L., Tu D., Pritchard K., et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005, 23:6931-6940. 10.1200/JC0.2005.11.181.
47. Cella D., Fallowfield L., Barker P., Cuzick J., Locker G., Howell A., et al. Quality of life of postmenopausal women in the ATAC (" Arimidex" , tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006, 100:273-284. 10.1007/s10549-006-9260-6.
48. Fallowfield L.J., Bliss J.M., Porter L.S., Price M.H., Snowdon C.F., Jones S.E., et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006, 24:910-917. 10.1200/JCO.2005.03.3654.
49. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. In: Presented at December 11, 2008. Annual San Antonio Breast Cancer Symposium (SABCS); 2008. Abstract 12.
50. Skedgel C., Rayson D., Dewar R., Younis T. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. Breast 2007, 16:252-261. 10.1016/j.breast.2006.12.002.
51. Lundkvist J., Wilking N., Holmberg S., Jonsson L. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat. 2007, 102:289-299. 10.1007/s10549-006-9333-6.
52. Delea T.E., El-Ouagari K., Karnon J., Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008, 108:375-387. 10.1007/s10549-007-9607-7.
53. Karnon J., Delea T., Johnston S.R.D., Smith R., Brandman J., Sung J., et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 2006, 24:237-250.
54. Mansel R., Locker G., Fallowfield L., Benedict A., Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', tamoxifen alone or in combination) tial. Br J Cancer. 2007, 97(2):152-161. 10.1038/sj.bjc.6603804.